A Phase 1b Study of Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel
- Indications Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 30 Mar 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2017.
- 30 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2017.
- 08 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.